Nicole has been helpful on the entire process. Thank you so much.
Lorraine Chan
3 months ago
Fresenius Kabi, LLC has issued a recall for Red Blood Cell (RBC) Set (catalog number 9007601), lot numbers WKT252, YLT061, ZCT011, and ZGT052, manufactured from October 1, 2007 to July 30, 2010. 255 units are subject to this recall. This US Food and Drug Administration (FDA) has deemed this recall Class I. Class I recalls […]
Fresenius Kabi, LLC has issued a recall for <"https://www.yourlawyer.com/practice_areas/defective_medical_devices">Red Blood Cell (RBC) Set (catalog number 9007601), lot numbers WKT252, YLT061, ZCT011, and ZGT052, manufactured from October 1, 2007 to July 30, 2010. 255 units are subject to this recall.
This US Food and Drug Administration (FDA) has deemed this recall Class I. Class I recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of these products will cause serious adverse health consequences or death.
Fresenius Kabi, LLC issued a Field Safety Corrective Action letter dated October 18, 2010 to their U.S. customers and followed up with telephone calls advising customers to examine their stock and determine if they have any affected products on hand.
Customers were instructed to discontinue distributing, using, and dispensing the affected products, and return the product to Fresenius Kabi, LLC, 8635 154th Avenue, NE, Redmond, Washington, 98052.
The consignees/customers were also instructed to notify their sub-account customers if the products were further distributed and to complete the Product Recall Response Form and fax it back to 1.425.242.2101.
Use of this device has led to removal of greater amounts of red blood cells than intended resulting in hemodilution. Hemodilution is an increase in the volume of plasma, which causes a reduction of red blood cells.
The firm indicates that the Red Blood Cell (RBC) Set (catalog number 9007601) is used for depletion or exchange of red blood cells during therapeutic apheresis procedures, when blood is removed from the patient and separated into its component parts, on the Fresenius AS 104 Blood Cell Separator Device.
The company is advising customers to discontinue using, dispensing, and distributing the affected product and return product to Fresenius Kabi, LLC.
Customers are also instructed to notify their sub-account customers if affected products were further distributed and to complete the Product Recall Response Form and fax it back to Fresenius Kabi at 1.425.242.2101.
Health care professionals and consumers may report adverse reactions or quality problems they experienced using these products to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by FAX.